SENSEX    38040.57       15.12    |    NIFTY    11214.05       13.90 FAQ    |    Feedback
EQUITIES
DERIVATIVES
IPO
COMMODITIES
Gainers & Losers Value & Volume Toppers 52 Weeks High/Low Advances & Declines
New High-Low
Pre-Session Mid-Session End-Session Other Markets Market Beat Stock Alert
Hot Pursuit Foreign Markets Economy News Corporate News Corporate Results
Detailed Quotes Board of Directors Balance Sheet Profit & Loss Quarterly Results Historical Price
Financial Ratios Company Background Technical Chart
Announcements Book Closure Board Meetings Bonus Issues Rights Issues
De-Listed Shares Name Change Split of Face Value Market Turnover
FII Investments MF Investments ADR Prices World Indices
Forthcoming IPOs
Open IPOs
Closed IPOs
New Listing
Basis Of Allotment Draft Prospectus New Issue Monitor
Get Quotes
Gainers
Losers
Value Toppers Advances & Declines Ticker Spot
Ticker Futures Closing Price Technical Chart Commodity News MCX Currency Futures
Get Quotes NIFTY Futures Top Traded Value Top Quantity Most Active Contracts
FII Statistics Daily Settlement Price List of Underlyings Put Call Ratio Derivative Summary
All Index Futures Top Gainers Top Losers Most Active Put Most Active Call
Highest in OI Lowest in OI Increase in OI Decrease in OI
Hot Pursuit
Scrips, which has significant changes during the market hours for last one week.
Sun Pharma records Q1 net loss of Rs 1656 cr
31-Jul-20   15:41 Hrs IST

Net sales declined 9.6% on a year-on-year (YoY) basis to Rs 7,467.19 crore in the first quarter of the financial year 2020-21. Research and development expenses rose 2.1% YoY to Rs 415.19 crore in Q1 June 2020.

Profit before tax and exceptional items fell 12% to Rs 1,449.43 crore in Q1 FY21 from Rs 1,647.44 crore in Q1 FY20.

The company recorded an exceptional expenditure of Rs 3,633.33 crore during the quarter ended 30 June 2020 on account of settlement of civil antitrust matters by Taro Pharmaceuticals U.S.A., Inc., Sun Pharma's subsidiary, with the United States' Department of Justice and certain other provisions relating to the same.

Pre-tax loss in Q1 FY21 stood at Rs 2,183.90 crore as against a pre-tax profit of Rs 1,647.44 recorded in the same period last year.

Tax expenses for the June quarter increased by 68.4% to Rs 245.91 crore compared with Rs 146.06 crore incurred in Q1 June 2019.

Meanwhile, the drug major's board approved the scheme of amalgamation and merger between the company and Sun Pharma Global FZE (wholly owned subsidiary of the company). It envisages merger of Sun Pharma Global FZE into the company. The scheme shall be effective post receipt of required approvals and accordingly, the above results do not reflect the impact on account of the scheme, Sun Pharma said.

The combined entity will have a bigger portfolio of products and direct access to markets, which will strengthen its capabilities to serve more efficiently its customers. This will also enable the SPIL address the competitive regulatory environment, risks and policies, better management of supply chain, better product profiling, greater differentiation, ability to strategize the Business for long term growth, the company said in a statement.

Shares of Sun Pharma jumped 4.27% to Rs 531.75 on Friday. It traded in the range of 507.75 and 540.75 during the day.

Sun Pharmaceutical Industries is a specialty generic manufacturing pharma company.

Powered by Capital Market - Live News

Currencies
Currency EUR GBP INR USD
Europe (EUR) 1.00 0.90 88.63 1.19
United Kingdom (GBP) 1.11 1.00 98.21 1.31
India (INR) 0.01 0.01 1.00 0.01
United States (USD) 0.84 0.76 74.70 1.00
Commodities << ALL Commodities
GOLDAHMD55922400
SILVERAHMD73755871
CRUDEOILMUMBAI3140-24
COPPERMUMBAI509.80.10
 Market News << ALL News
   Disclaimer   |   BSE Disclosure  |   Privacy Policy   |   Investor Protection   |   Inactive Account
Feedback   |   PMLA Policy   |   Risk Management Policy   |   Insider Trading   
  
   Investor Grivenances   |   Investor Complaints   |   Rules And Regulations   |   Broker Norms   |   Terms of Use SEBI Registration No : INZ000267132   |   BSE Clearing No : 333   
   Copyright © 2011 All rights reserved by Jaysukhlal Jagjivan Stock Broking Pvt.Ltd Designed, Developed & Powered By CMOTS INFOTECH (ISO 9001:2015 certified)